他克莫司在20例肝移植中的应用  

Application of FK506 in 20 cases of liver transplantation

作　　者：叶启发[1] 沙波[1] 宫念樵[1] 田超睿[1] 夏穗生[1] 

机构地区：[1]同济医科大学附属同济医院器官移植研究所,武汉430030

出　　处：《中华器官移植杂志》2000年第4期240-241,共2页Chinese Journal of Organ Transplantation

摘　　要：目的　探讨他克莫司 (FK5 0 6 )在肝移植中的应用方法。方法　 2 0例肝移植患者随机分为FK5 0 6高浓度组、FK5 0 6中浓度组、CsA转换为FK5 0 6组、FK5 0 6转换为CsA组。观察各组临床表现、药物副作用和病理学变化。结果　FK5 0 6高浓度组容易出现感染、药物性肝损害等不良表现 ,FK5 0 6中浓度组虽也出现多种并发症 ,但易于处理。结论　FK5 0 6是一种高效免疫抑制剂 ,FK5 0Objective To study the application of FK506 in liver transplantation. Methods Twenty cases of liver transplantation were randomly divided into high dose FK506 group, moderate dose FK506 group, CsA FK506 group and FK506 CsA group. The clinical manifestation, side effects of FK506 and pathological changes were observed in each group. Results The patients in the high dose FK506 group were susceptible to infection and drug induced liver injury. The patients in the moderate dose FK506 got an excellent therapeutic effects and the complications were easy to treat. Conclusions FK506 is a high effective immunosuppressive agent and the moderate dose protocol is a better one.

关 键 词：免疫抑制剂 肝移植 他克莫司 临床应用 

分 类 号：R657.3[医药卫生—外科学] R979.5[医药卫生—临床医学]